Search In this Thesis
   Search In this Thesis  
العنوان
Evaluation the role of lipocalin 2 as a new noninvasive diagnostic marker for hepatocellular
carcinoma in Egyptian cirrhotic patients /
المؤلف
Abd EL-Mabood, Menna Alla Mostafa Sediq.
هيئة الاعداد
باحث / منة الله مصطفى صديق عبدالمعبود
مشرف / إنجي يسري السيد عاشور
مشرف / حسام سمير إبراهيم الباز
مشرف / شريف أحمد مجاهد أحمد
تاريخ النشر
2022.
عدد الصفحات
122 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الكبد
تاريخ الإجازة
1/1/2022
مكان الإجازة
جامعة عين شمس - كلية الطب - قسم الباطنة العامة والجهاز الهضمى والكبد
الفهرس
Only 14 pages are availabe for public view

from 122

from 122

Abstract

We concluded from this study that:
 Serum LCN 2 level was significantly higher in patients with HCC regardless of other characterstics as presence of combined conditions as DM and HTN or Viral markers and mildly elevated in patients with liver cirrhosis compared to the control group.
 LCN 2 is more sensitive and accurate than AFP in diagnosis of HCC.
 Useing of LCN 2 will improve the diagnostic field and can help in early detection of HCC in surveillance programms.
.
.
Recommendations
 Using lipocalin 2 as a marker in early detection of HCC in surveillance programms instead of AFP.
.
.
Summary
Hepatocellular carcinoma HCC is now the sixth most common cause of cancer worldwide. The second leading cause of cancer death after lung cancer in men is HCC.
The most frequently used screening tests for HCC patients are hepatic ultrasound (US) with or without assessment of alpha-fetoprotein, but the diagnostic value of AFP is recently challenged due to its low sensitivity and specificity.
So the aim of this study was to evaluate the role of LCN 2 as a diagnostic marker in HCC Egyptian patients .
The study was carried out on 96 Egyptian patients
group A (Hcc): 32 patients with Hepatocellular carcinoma, age ranged from 50 to 74 , (there were 24 male patients , 8 female patients), all of them had at least one hepatic focal lesion.
group B (Cirrhotic): 32 patients with liver cirrhosis without Hepatocellular carcinoma, age ranged from 32 to 70 (there were 22 male patients , 10 female patients).
group C (control) :32 apparently healthy subjects for detecting normal value of the marker, age and sex matched, having no acute or chronic illness and taking no medications were taken as control group.
For all participant in this study, full clinical assessment by history and physical examination in addition to laboratory hematological and biochemical assessment and confirmation of HCC diagnosis was done by triphasic CT on the abdomen, We assessed serum LCN 2 in all study participant.
In this study , we found HCC was more in old age and male patient, who had DM , HTN and HCV which were risk factors for hcc.
We found that LCN 2 level ranged from 150 to 380 in HCC group with mean±SD = 292.750±50.940 , from 88 to 280 in cirrhotic patients with mean± SD = 129.313±36.605, from 40 to 62 in control group with mean± SD = 53.250± 4.958, being statistically significant higher in HCC group more than both cirrhotic group and control group and in cirrhotic patients more than control group (p-value =<0.001 ).
LCN 2 was found slightly elevated in cirrhotic patients compared to healthy controls , suggesting that LCN 2 level increase in liver damage , however the significance was much lower than that from a comparison between the cirrhosis and hcc groups .
The results showed, there was significant positive correlation between age, GGT , child score and size of hepatic focal lesions in hcc, and LCN 2 among HCC group that prove LCN 2 level increase in hcc.
There was no significant correlation between LCN 2 and (WBCs, HB, PLT, BUN, Creat, Na , K, Total and direct bilirubin, AST, ALT, ALP, INR, AFP, BMI and MELD Score ) among both HCC group and cirrhotic group.
There was no significant correlation between LCN 2 and number of hepatic focal lesion in hcc group.
While there was significant negative correlation between albumin and LCN 2 among HCC group (r-value= -0.358 , p-value=0.044 ) .
The results showed sensitivity 96.87% and specificity 96.87% for LCN 2 as a marker for HCC with accuracy of 98.4% , with cut off > 160.
While showed sensitivity 93.75% and specificity 96.87% with accuracy of 96.4% for AFP IN HCC.
Lipocalin 2 is more sensitive and accurate than AFP in diagnosis of HCC.
The presence of (LCN-2) in blood , is a biomarker of early stages of HCC.
LCN 2 is a promising serum tumor marker for HCC diagnosis.